Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron's CBO hops ship to lead startup
→ After passing their third straight Phase III trial for its new kind of diabetes tablet in Japan, French pharma Poxel
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
